Literature DB >> 11919187

In vitro selection of RNA aptamers that bind to cell adhesion receptors of Trypanosoma cruzi and inhibit cell invasion.

Henning Ulrich1, Margaret H Magdesian, Maria Julia M Alves, Walter Colli.   

Abstract

Trypanosoma cruzi causing Chagas' disease needs to invade host cells to complete its life cycle. Macromolecules on host cell surfaces such as laminin, thrombospondin, heparan sulfate, and fibronectin are believed to be important in mediating parasite-host cell adhesions and in the invasion process of the host cell by the parasite. The SELEX technique (systematic evolution of ligands by exponential enrichment) was used to evolve nuclease-resistant RNA ligands (aptamer = to fit) that bind with affinities of 40-400 nm to parasite receptors for the host cell matrix molecules laminin, fibronectin, thrombospondin, and heparan sulfate. After eight consecutive rounds of in vitro selection four classes of RNA aptamers based on structural similarities were isolated and sequenced. All members of each class shared a common sequence motif and competed with the respective host cell matrix molecule that was used for displacement during the selection procedure. RNA pools following seven and eight selection rounds as well as individual aptamers sharing consensus motifs were active in inhibiting invasion of LLC-MK(2) monkey kidney cells by T. cruzi in vitro.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11919187     DOI: 10.1074/jbc.M111859200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  In vitro selection of RNA aptamers directed against protein E: a Haemophilus influenzae adhesin.

Authors:  Anders Barfod; Birendra Singh; Urban Johanson; Kristian Riesbeck; Per Kjellbom
Journal:  Mol Biotechnol       Date:  2014-08       Impact factor: 2.695

2.  RNA sequence and secondary structure participate in high-affinity CsrA-RNA interaction.

Authors:  Ashok K Dubey; Carol S Baker; Tony Romeo; Paul Babitzke
Journal:  RNA       Date:  2005-08-30       Impact factor: 4.942

3.  In vitro RNA random pools are not structurally diverse: a computational analysis.

Authors:  Jana Gevertz; Hin Hark Gan; Tamar Schlick
Journal:  RNA       Date:  2005-06       Impact factor: 4.942

4.  In vivo biodistribution and pharmacokinetics of 18F-labelled Spiegelmers: a new class of oligonucleotidic radiopharmaceuticals.

Authors:  Raphaël Boisgard; Bertrand Kuhnast; Stefan Vonhoff; Chéraz Younes; Françoise Hinnen; Jean-Marc Verbavatz; Bernard Rousseau; Jens Peter Fürste; Britta Wlotzka; Frédéric Dollé; Sven Klussmann; Bertrand Tavitian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12-22       Impact factor: 9.236

5.  REGULATION of the EXTRACELLULAR MATRIX INTERACTOME by Trypanosoma cruzi.

Authors:  Tatiana C Cardenas; Candice A Johnson; Siddharth Pratap; Pius N Nde; Vyacheslav Furtak; Yuliya Y Kleshchenko; Maria F Lima; Fernando Villalta
Journal:  Open Parasitol J       Date:  2010

Review 6.  Molecular imaging with nanoparticles: giant roles for dwarf actors.

Authors:  Paul Debbage; Werner Jaschke
Journal:  Histochem Cell Biol       Date:  2008-09-30       Impact factor: 4.304

7.  Aptamer–biotin–streptavidin–C1q complexes can trigger the classical complement pathway to kill cancer cells.

Authors:  John Gordon Bruno
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-02       Impact factor: 2.416

Review 8.  Designed and Evolved Nucleic Acid Nanotechnology: Contrast and Complementarity.

Authors:  Tulsi Ram Damase; Peter B Allen
Journal:  Bioconjug Chem       Date:  2019-01-03       Impact factor: 4.774

9.  Strategies for the discovery of therapeutic aptamers.

Authors:  Xianbin Yang; Na Li; David G Gorenstein
Journal:  Expert Opin Drug Discov       Date:  2011-01       Impact factor: 6.098

Review 10.  Molecular aptamers for drug delivery.

Authors:  Weihong Tan; Hui Wang; Yan Chen; Xiaobing Zhang; Haizhen Zhu; Chaoyong Yang; Ronghua Yang; Chen Liu
Journal:  Trends Biotechnol       Date:  2011-08-06       Impact factor: 19.536

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.